Tackling supply chain challenges for a country at war
We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.
Search
The impact of carbon reduction projects
Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Update Israel and Gaza conflict
Update on Israel and the Palestine territories
Diabetic macular edema and diabetic macular ischemia
Diabetic macular edema and diabetic macular ischemia are complications of diabetic retinopathy.
The status of schizophrenia care
A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
Patient centricity and site centricity in clinical trials
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
Media & Stories
Media & Stories
PRRS vaccine discovery for swine
PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Annual Press Conference 2024
Boehringer Ingelheim presents the 2023 results and an outlook for 2024 at the Annual Press Conference on April 16, 2024.
Speak Up – Compliance Hotline
The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
Newsletter
Newsletter
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Neovascular AMD (wet AMD)
Neovascular AMD (or wet AMD) is a severe form of advanced age-related macular degeneration that can lead to irreversible vision loss if untreated
Human Health Innovation
Human Health Innovation
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
International Postdocs realize their potential in Biberach
Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.
Building blocks of our future
Our global investment projects are the building blocks for improved healthcare and sustainability
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Innovation Prize Winners
Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Internal application
Internal applications | FAQ
Annual Results Press Conference 2023
Boehringer Ingelheim presents the 2022 results and an outlook for 2023 at the Annual Press Conference on March 29, 2023.
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.